Effectiveness of proton pump inhibitors in nonerosive reflux disease

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 8, 2004, Pages 656-664

  Dean, Bonnie B ^a,d   Gano Jr , Anacleto D ^a   Knight, Kevin ^a   Ofman, Joshua J ^a,b   Fass, Ronnie ^c  

^a Cerner Health Insights   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^d 90212 ^*  (United States)

Author keywords

CI; confidence interval; EE; erosive esophagitis; gastroesophageal reflux disease; GERD; NERD; nonerosive reflux disease; PPI; proton pump inhibitor

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CLINICAL TRIAL; COMPARATIVE STUDY; ERYTHEMA; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MEDICAL LITERATURE; NONEROSIVE GASTROINTESTINAL REFLUX DISEASE; REFLUX ESOPHAGITIS; REVIEW;

EID: 3543024548     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00288-5     Document Type: Article

References (30)

1. Kahrilas P.J. Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 98:2003;S15-S23
2. Green J.R.B. Is there such an entity as mild oesophagitis? Eur J Clin Res. 4:1993;29-34
3. Laursen L.S., Havelund T., Bondesen S., Hansen J., Sanchez G., Sebelin E., Fenger C., Lauritsen K. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scand J Gastroenterol. 30:1995;839-846
4. Kuster E., Ros E., Toledo-Pimentel V., Pujol A., Bordas J.M., Grande L., Pera C. Predictive factors of the long term outcome in gastro-oesophageal reflux disease six year follow up of 107 patients. Gut. 35:1994;8-14
5. Trimble K.C., Douglas S., Pryde A., Heading R.C. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci. 40:1995;1098-1104
6. Chiba N., De Gara C.J., Wilkinson J.M., Hunt R.H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease a meta-analysis. Gastroenterology. 112:1997;1798-1810
7. Fass R., Fennerty M.B., Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol. 96:2001;303-314
8. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 98:2003;S2-S7
9. Hetzel D.J., Dent J., Reed W.D., Narielvala F.M., Mackinnon M., McCarthy J.H., Mitchell B., Beveridge B.R., Laurence B.H., Gibson G.G. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 95:1988;903-912
10. Lind T., Havelund T., Carlsson R., Anker-Hansen O., Glise H., Hernqvist H., Junghard O., Lauritsen K., Lundell L., Pedersen S.A., Stubberod A. Heartburn without oesophagitis efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 32:1997;974-979
11. Hatlebakk J.G. Heartburn treatment in primary care randomised, double blind study for 8 weeks. BMJ. 319:1999;550-553
12. Richter J.E., Peura D., Benjamin S.B., Joelsson B., Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med. 160:2000;1810-1816
13. AstraZeneca. A comparative efficacy and safety study of H 199/18 (20mg), H 199/18 (40mg) vs. placebo in study subjects with symptomatic GERD. 1999;. FDA Report 21-153-225.
14. AstraZeneca. A comparative efficacy and safety study of H 199/18 (20mg), H 199/18 (40mg) vs placebo in study subjects with symptomatic GERD. 1999;. FDA Report 21-153-226.
15. Janssen. A placebo-controlled trial of rabeprazole tablets, 10mg QD or 20mg QD, in the treatment of subjects with symptoms of chronic Gastroesophageal Reflux Disease (GERD). 2000;. FDA Report 20-973-RAB-USA-2
16. Janssen. A double-blind, placebo-controlled trial of rabeprazole tablets, 20 mg once daily, in the treatment of subjects without erosive esophagitis and who have symptoms of chronic gastroesophageal reflux disease (GERD). 2001;. FDA Report 20-973-RAB-USA-3
17. Cloud M.L., Enas N., Humphries T.J., Bassion S. The Rabeprazole Study Group. Rabeprazole in treatment of acid peptic diseases results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci. 43:1998;993-1000
18. Richter J.E., Bochenek W. Pantoprazole US GERD Study Group. Oral pantoprazole for erosive esophagitis a placebo-controlled, randomized clinical trial. Am J Gastroenterol. 95:2000;3071-3080
19. Sabesin S.M., Berlin R.G., Humphries T.J., Bradstreet D.C., Walton-Bowen K.L., Zaidi S. USA Merck Gastroesophageal Reflux Disease Study Group. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. [see comments] Arch Intern Med. 151:1991;2394-2400
20. Kahrilas P.J., Fennerty M.B., Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease a prospective, controlled trial. Am J Gastroenterol. 94:1999;92-97
21. Hatlebakk J.G., Johnsson F., Vilien M., Carling L., Wetterhus S., Thogersen T. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scand J Gastroenterol. 32:1997;1100-1106
22. Bate C.M., Griffin S.M., Keeling P.W., Axon A.T., Dronfield M.W., Chapman R.W., O'Donoghue D., Calam J., Crowe J., Mountfords R.A., Watts D.A., Taylor M.D., Richardson P.D. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 10:1996;547-555
23. Venables T.L., Newland R.D., Patel A.C., Hole J., Wilcock C., Turbitt M.L. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 32:1997;965-973
24. Richter J.E., Campbell D.R., Kahrilas P.J., Huang B., Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 160:2000;1803-1809
25. Galmiche J.P., Barthelemy P., Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 11:1997;765-773
26. Isolauri J., Luostarinen M., Isolauri E., Reinikainen P., Viljakka M., Keyrilainen O. Natural course of gastroesophageal reflux disease 17-22 year follow-up of 60 patients. Am J Gastroenterol. 92:1997;37-41
27. Fass R., Ofman J.J. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol. 97:2002;1901-1909
28. Martinez S.D., Malagon I.B., Garewal H.S., Cui H., Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther. 17:2003;537-545
29. Harding S.M., Richter J.E., Guzzo M.R., Schan C.A., Alexander R.W., Bradley L.A. Asthma and gastroesophageal reflux acid suppressive therapy improves asthma outcome. Am J Med. 100:1996;395-405
30. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., McQuay H.J. Assessing the quality of reports of randomized clinical trials is blinding necessary? Control Clin Trials. 17:1996;1-12